John A. H. Wass
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John A. H. Wass has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Niki Karavitaki
Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham , Birmingham B15 2TT
16 shared publications Cristina Capatina
3 shared publicationsH. E. Turner
Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK
3 shared publicationsHelen E. Turner
Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
3 shared publicationsOlaf Ansorge
The John Radcliffe Hospital
3 shared publicationsAlberto Fernandez
Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK
2 shared publications
Latest Publications
- 12 October 2015
- Published by Bioscientifica in Endocrine Abstracts
Mortality of patients with non-functioning pituitary macroadenoma is significantly elevated: systematic analysis of 546 cases in a tertiary referral centre in the UK
Introduction: Data on the mortality of patients with non-functioning pituitary macroadenoma (NFA) are limited. Aim: To assess the mortality of patients with NFA and predictive factors. Patients/methods: All patients presenting to our Department with NFA between 1963 and 2011 were studied. Status was recorded as either dead or alive, as of 31 December 2011. Results: 546 patients (333 males) were identified (median age at surgery 58.7 years; range 16.1–94.2). Data on mortality were available for all patients covering a median period of 8 years (range 1 month-48.5 years); 83 patients died (median age 77.8 years; range 36.4–98.3) (causes: cardio/cerebrovascular 33.7%, infections 30.1%, malignancies 28.9%, peri-operatively 1.2%, gastrointestinal haemorrhage 1.2%, suicide 1.2%, unknown 2.4%, old age 1.2%). SMR for total group:3.62 (95% CI:2.90–4.47; P<0.001), for those diagnosed before 1990:4.66 (95% CI:2.65–7.63; P<0.001) and for those after 1990:3.53 (95% CI:2.77–4.44; P<0.001). Clinical follow-up data (until date of death or date the database was frozen) were available for 436 patients [269 males, median age at surgery 58.5 years; range 16.11–94.19), 203/431 with no or intrasellar remnant – 228/431 with extrasellar remnant after surgery, median follow-up 6.9 years (range 1 month-48.5 years), 111/436 with NFA regrowth, 188/436 received radiotherapy adjuvant or for regrowth]. Cox regression analysis (univariate followed by multivariate approach) demonstrated that amongst age at surgery, NFA regrowth, radiotherapy, sex, extent of removal, untreated GH deficiency, untreated FSH/LH deficiency, ACTH deficiency, TSH deficiency and treatment with DDAVP, only age remained an independent significant factor (HR 1.099, 95% CI: 1.073–1.126; P<0.001). Conclusions: This is the first study assessing mortality in a large series of non-selected patients with NFA in the UK. Despite the improvement in the last three decades, mortality remains high. Apart from age, factors related with the management/outcome of the tumour are not independent predictors and pituitary hormone deficits managed with the currently used substitution protocols do not adversely affect mortality in this group of patients.
- 12 October 2015
- Published by Bioscientifica in Endocrine Abstracts
Mortality of patients with non-functioning pituitary macroadenoma is significantly elevated: systematic analysis of 546 cases in a tertiary referral centre in the UK
Introduction: Data on the mortality of patients with non-functioning pituitary macroadenoma (NFA) are limited. Aim: To assess the mortality of patients with NFA and predictive factors. Patients/methods: All patients presenting to our Department with NFA between 1963 and 2011 were studied. Status was recorded as either dead or alive, as of 31 December 2011. Results: 546 patients (333 males) were identified (median age at surgery 58.7 years; range 16.1–94.2). Data on mortality were available for all patients covering a median period of 8 years (range 1 month-48.5 years); 83 patients died (median age 77.8 years; range 36.4–98.3) (causes: cardio/cerebrovascular 33.7%, infections 30.1%, malignancies 28.9%, peri-operatively 1.2%, gastrointestinal haemorrhage 1.2%, suicide 1.2%, unknown 2.4%, old age 1.2%). SMR for total group:3.62 (95% CI:2.90–4.47; P<0.001), for those diagnosed before 1990:4.66 (95% CI:2.65–7.63; P<0.001) and for those after 1990:3.53 (95% CI:2.77–4.44; P<0.001). Clinical follow-up data (until date of death or date the database was frozen) were available for 436 patients [269 males, median age at surgery 58.5 years; range 16.11–94.19), 203/431 with no or intrasellar remnant – 228/431 with extrasellar remnant after surgery, median follow-up 6.9 years (range 1 month-48.5 years), 111/436 with NFA regrowth, 188/436 received radiotherapy adjuvant or for regrowth]. Cox regression analysis (univariate followed by multivariate approach) demonstrated that amongst age at surgery, NFA regrowth, radiotherapy, sex, extent of removal, untreated GH deficiency, untreated FSH/LH deficiency, ACTH deficiency, TSH deficiency and treatment with DDAVP, only age remained an independent significant factor (HR 1.099, 95% CI: 1.073–1.126; P<0.001). Conclusions: This is the first study assessing mortality in a large series of non-selected patients with NFA in the UK. Despite the improvement in the last three decades, mortality remains high. Apart from age, factors related with the management/outcome of the tumour are not independent predictors and pituitary hormone deficits managed with the currently used substitution protocols do not adversely affect mortality in this group of patients.
- 1 May 2015
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 172 (5) , R179-R190
MANAGEMENT OF ENDOCRINE DISEASE: Pituitary tumour apoplexy
Pituitary tumour apoplexy (PA) is a rare clinical syndrome that occurs as a result of acute haemorrhage and/or infarction within a frequently undiagnosed pituitary tumour. The sudden enlargement of the pituitary mass undergoing PA is responsible for a wide range of acute symptoms/signs (severe headache, visual loss, diplopia, hypopituitarism, impaired consciousness) which, together with the radiological evidence of a pituitary lesion, establish the diagnosis. The optimal care of PA requires involvement of a multidisciplinary team including endocrinologist, neurosurgeon, neuroophthalmologist and the management strategy that depends on the clinical manifestations, as well as the presence of co-morbidities. Prompt surgical decompression is initially indicated in cases with severe or progressive impairment of the visual acuity or the visual fields or with altered mental state and leads to visual and neurological recovery in most of the patients. The patients with mild, stable clinical picture (including those with isolated ocular palsies) can be managed conservatively (support of fluid and electrolyte balance and stress doses of steroids in most cases) with favourable visual and neurological outcome. Frequent reassessment is mandatory because the clinical course can be unpredictable; if progression of symptoms occurs, later elective surgery is indicated and is beneficial, especially in terms of visual outcome. The endocrinological outcome is less favourable, irrespective of the treatment option, with many patients remaining on long-term replacement therapy. Despite the above guidelines, clear proof of optimal outcomes in the form of randomised controlled trials is lacking. Regrowth of the pituitary tumour years after a PA episode is possible and patients require long-term surveillance.
- 1 May 2015
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 172 (5) , R179-R190
MANAGEMENT OF ENDOCRINE DISEASE: Pituitary tumour apoplexy
Pituitary tumour apoplexy (PA) is a rare clinical syndrome that occurs as a result of acute haemorrhage and/or infarction within a frequently undiagnosed pituitary tumour. The sudden enlargement of the pituitary mass undergoing PA is responsible for a wide range of acute symptoms/signs (severe headache, visual loss, diplopia, hypopituitarism, impaired consciousness) which, together with the radiological evidence of a pituitary lesion, establish the diagnosis. The optimal care of PA requires involvement of a multidisciplinary team including endocrinologist, neurosurgeon, neuroophthalmologist and the management strategy that depends on the clinical manifestations, as well as the presence of co-morbidities. Prompt surgical decompression is initially indicated in cases with severe or progressive impairment of the visual acuity or the visual fields or with altered mental state and leads to visual and neurological recovery in most of the patients. The patients with mild, stable clinical picture (including those with isolated ocular palsies) can be managed conservatively (support of fluid and electrolyte balance and stress doses of steroids in most cases) with favourable visual and neurological outcome. Frequent reassessment is mandatory because the clinical course can be unpredictable; if progression of symptoms occurs, later elective surgery is indicated and is beneficial, especially in terms of visual outcome. The endocrinological outcome is less favourable, irrespective of the treatment option, with many patients remaining on long-term replacement therapy. Despite the above guidelines, clear proof of optimal outcomes in the form of randomised controlled trials is lacking. Regrowth of the pituitary tumour years after a PA episode is possible and patients require long-term surveillance.
- 1 March 2015
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 44 (1) , 127-141
Hypopituitarism
- 1 March 2015
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 44 (1) , 127-141
Hypopituitarism
- 8 July 2011
- Published by Springer Nature in Osteoporosis International
- Vol. 23 (1) , 285-294
Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists
Bisphosphonates can increase bone mineral density (BMD) in children with osteogenesis imperfecta (OI). In this study of adults with OI type I, risedronate increased BMD at lumbar spine (but not total hip) and decreased bone turnover. However, the fracture rate in these patients remained high. Intravenous bisphosphonates given to children with OI can increase BMD and reduce fracture incidence. Oral and/or intravenous bisphosphonates may have similar effects in adults with OI. We completed an observational study of the effect of risedronate in adults with OI type I. Thirty-two adults (mean age, 39 years) with OI type I were treated with risedronate (total dose, 35 mg weekly) for 24 months. Primary outcome measures were BMD changes at lumbar spine (LS) and total hip (TH). Secondary outcome measures were fracture incidence, bone pain, and change in bone turnover markers (serum procollagen type I aminopropeptide (P1NP) and bone ALP). A meta-analysis of published studies of oral bisphosphonates in adults and children with OI was performed. Twenty-seven participants (ten males and seventeen females) completed the study. BMD increased at LS by 3.9% (0.815 vs. 0.846 g/cm2, p = 0.007; mean Z-score, −1.93 vs. −1.58, p = 0.002), with no significant change at TH. P1NP fell by 37% (p = 0.00041), with no significant change in bone ALP (p = 0.15). Bone pain did not change significantly (p = 0.6). Fracture incidence remained high, with 25 clinical fractures and 10 major fractures in fourteen participants (0.18 major fractures per person per year), with historical data of 0.12 fractures per person per year. The meta-analysis did not demonstrate a significant difference in fracture incidence in patients with OI treated with oral bisphosphonates. Risedronate in adults with OI type I results in modest but significant increases in BMD at LS, and decreased bone turnover. However, this may be insufficient to make a clinically significant difference to fracture incidence.
- 8 July 2011
- Published by Springer Nature in Osteoporosis International
- Vol. 23 (1) , 285-294
Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists
Bisphosphonates can increase bone mineral density (BMD) in children with osteogenesis imperfecta (OI). In this study of adults with OI type I, risedronate increased BMD at lumbar spine (but not total hip) and decreased bone turnover. However, the fracture rate in these patients remained high. Intravenous bisphosphonates given to children with OI can increase BMD and reduce fracture incidence. Oral and/or intravenous bisphosphonates may have similar effects in adults with OI. We completed an observational study of the effect of risedronate in adults with OI type I. Thirty-two adults (mean age, 39 years) with OI type I were treated with risedronate (total dose, 35 mg weekly) for 24 months. Primary outcome measures were BMD changes at lumbar spine (LS) and total hip (TH). Secondary outcome measures were fracture incidence, bone pain, and change in bone turnover markers (serum procollagen type I aminopropeptide (P1NP) and bone ALP). A meta-analysis of published studies of oral bisphosphonates in adults and children with OI was performed. Twenty-seven participants (ten males and seventeen females) completed the study. BMD increased at LS by 3.9% (0.815 vs. 0.846 g/cm2, p = 0.007; mean Z-score, −1.93 vs. −1.58, p = 0.002), with no significant change at TH. P1NP fell by 37% (p = 0.00041), with no significant change in bone ALP (p = 0.15). Bone pain did not change significantly (p = 0.6). Fracture incidence remained high, with 25 clinical fractures and 10 major fractures in fourteen participants (0.18 major fractures per person per year), with historical data of 0.12 fractures per person per year. The meta-analysis did not demonstrate a significant difference in fracture incidence in patients with OI treated with oral bisphosphonates. Risedronate in adults with OI type I results in modest but significant increases in BMD at LS, and decreased bone turnover. However, this may be insufficient to make a clinically significant difference to fracture incidence.
- Open Access
- 29 August 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 462
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone
Background: Giant cell tumour of bone (GCTB) is an expansile osteolytic tumour which contains numerous osteoclast-like giant cells. GCTB frequently recurs and can produce metastatic lesions in the lungs. Bisphosphonates are anti-resorptive drugs which act mainly on osteoclasts. Method: In this study, we have examined clinical and radiological outcomes of treatment with aminobisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four European centres. We also analysed in vitro the inhibitory effect of zoledronic acid on osteoclasts isolated from GCTBs. Results: Treatment protocols differed with several different aminobisphosphonates being employed, but stabilisation of disease was achieved in most of these cases which were refractory to conventional treatment. Most inoperable sacral/pelvic tumours did not increase in size and no further recurrence was seen in GCTBs that had repeatedly recurred in bone and soft tissues. Lung metastases did not increase in size or number following treatment. Zoledronic acid markedly inhibited lacunar resorption by GCTB-derived osteoclasts in vitro. Conclusion: Our findings suggest that bisphosphonates may be useful in controlling disease progression in GCTB and that these agents directly inhibit GCTB - derived osteoclast resorption. These studies highlight the need for the establishment of standardised protocols to assess the efficacy of bisphosphonate treatment of GCTB.
- 29 August 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 462
Open AccessBisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone
Background: Giant cell tumour of bone (GCTB) is an expansile osteolytic tumour which contains numerous osteoclast-like giant cells. GCTB frequently recurs and can produce metastatic lesions in the lungs. Bisphosphonates are anti-resorptive drugs which act mainly on osteoclasts. Method: In this study, we have examined clinical and radiological outcomes of treatment with aminobisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four European centres. We also analysed in vitro the inhibitory effect of zoledronic acid on osteoclasts isolated from GCTBs. Results: Treatment protocols differed with several different aminobisphosphonates being employed, but stabilisation of disease was achieved in most of these cases which were refractory to conventional treatment. Most inoperable sacral/pelvic tumours did not increase in size and no further recurrence was seen in GCTBs that had repeatedly recurred in bone and soft tissues. Lung metastases did not increase in size or number following treatment. Zoledronic acid markedly inhibited lacunar resorption by GCTB-derived osteoclasts in vitro. Conclusion: Our findings suggest that bisphosphonates may be useful in controlling disease progression in GCTB and that these agents directly inhibit GCTB - derived osteoclast resorption. These studies highlight the need for the establishment of standardised protocols to assess the efficacy of bisphosphonate treatment of GCTB.
- 9 November 2009
- Published by Wiley in Clinical Endocrinology
- Vol. 71 (6) , 840-845
The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly
BACKGROUND: The nadir GH value following an oral glucose tolerance test (OGTT) and the mean GH levels obtained from a GH day curve (GHDC) are among the tools currently used for assessing therapeutic end-points in surgically treated acromegaly. The latter test, however, is cumbersome and costly. OBJECTIVES: To evaluate, by using a modern, two-site chemiluminescent immunometric GH assay, the degree of discordance between the nadir GH following an OGTT and the mean GH obtained from a GHDC after surgical treatment of acromegaly and to check whether the OGTT can replace reliably the GHDC for the assessment of the disease status postoperatively. PATIENTS AND METHODS: Forty-nine patients [25 males/24 females, median age 52 years (range 18-70)] with a GH-secreting pituitary adenoma who had been surgically treated previously underwent hormonal evaluation of their disease status. The GHDC comprised of 9 x 30-min samples for GH collected in the morning after an overnight fast and rest. RESULTS: Seven per cent of patients with mean GH 0.7 mug/l (2 mU/l) in the OGTT, and 10% of those with mean GH >1.7 mug/l had nadir GH <0.7 mug/l in the OGTT (all cases with discrepancies had normal IGF-I). GH value at time 0 min <0.6 mug/l in the OGTT had positive predictive value 100% and negative predictive value 75% in predicting nadir GH <0.3 mug/l (1 mU/l) in the OGTT. Nadir GH <0.8 mug/l in the OGTT had positive predictive value 97% and negative predictive value 95% in predicting mean GH <1.7 mug/l in the GHDC. Mean GH in the OGTT <1.4 mug/l had a positive predictive value 90% and negative predictive value 95% in predicting mean GH <1.7 mug/l in the GHDC. Mean GH in the OGTT <2.5 mug/l had positive predictive value 100% and negative predictive value 81% in predicting normal IGF-I. GH at time 0 min in the GHDC <2.1 mug/l had positive predictive value 90% and negative predictive value 90% in predicting mean GH <1.7 mug/l in the GHDC. CONCLUSIONS: The hormonal data obtained from an OGTT (mean and nadir GH) can provide comprehensive information on the status of acromegaly following surgery and can replace the GHDC cost-effectively. Furthermore, a morning fasting GH sample has an excellent positive predictive value in predicting biochemical cure and an optimal prognostic profile in predicting "safe" mean GH levels
- 9 November 2009
- Published by Wiley in Clinical Endocrinology
- Vol. 71 (6) , 840-845
The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly
BACKGROUND: The nadir GH value following an oral glucose tolerance test (OGTT) and the mean GH levels obtained from a GH day curve (GHDC) are among the tools currently used for assessing therapeutic end-points in surgically treated acromegaly. The latter test, however, is cumbersome and costly. OBJECTIVES: To evaluate, by using a modern, two-site chemiluminescent immunometric GH assay, the degree of discordance between the nadir GH following an OGTT and the mean GH obtained from a GHDC after surgical treatment of acromegaly and to check whether the OGTT can replace reliably the GHDC for the assessment of the disease status postoperatively. PATIENTS AND METHODS: Forty-nine patients [25 males/24 females, median age 52 years (range 18-70)] with a GH-secreting pituitary adenoma who had been surgically treated previously underwent hormonal evaluation of their disease status. The GHDC comprised of 9 x 30-min samples for GH collected in the morning after an overnight fast and rest. RESULTS: Seven per cent of patients with mean GH 0.7 mug/l (2 mU/l) in the OGTT, and 10% of those with mean GH >1.7 mug/l had nadir GH <0.7 mug/l in the OGTT (all cases with discrepancies had normal IGF-I). GH value at time 0 min <0.6 mug/l in the OGTT had positive predictive value 100% and negative predictive value 75% in predicting nadir GH <0.3 mug/l (1 mU/l) in the OGTT. Nadir GH <0.8 mug/l in the OGTT had positive predictive value 97% and negative predictive value 95% in predicting mean GH <1.7 mug/l in the GHDC. Mean GH in the OGTT <1.4 mug/l had a positive predictive value 90% and negative predictive value 95% in predicting mean GH <1.7 mug/l in the GHDC. Mean GH in the OGTT <2.5 mug/l had positive predictive value 100% and negative predictive value 81% in predicting normal IGF-I. GH at time 0 min in the GHDC <2.1 mug/l had positive predictive value 90% and negative predictive value 90% in predicting mean GH <1.7 mug/l in the GHDC. CONCLUSIONS: The hormonal data obtained from an OGTT (mean and nadir GH) can provide comprehensive information on the status of acromegaly following surgery and can replace the GHDC cost-effectively. Furthermore, a morning fasting GH sample has an excellent positive predictive value in predicting biochemical cure and an optimal prognostic profile in predicting "safe" mean GH levels
- Open Access
- 1 September 2009
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 16 (3) , 733-772
Radiation-induced hypopituitarism
The hypothalamic–pituitary unit is a particularly radiosensitive region in the central nervous system. As a consequence, hypopituitarism commonly develops after radiation treatments for sellar and parasellar neoplasms, extrasellar brain tumours, head and neck tumours, and following whole body irradiation for systemic malignancies. Increasing tumour-related survival rates provide an expanding population at risk of developing hypopituitarism. In this population, long-term monitoring tailored to the individual risk profile is required to avoid the sequelae of untreated pituitary hormonal deficiencies and resultant decrease in the quality of life. This review analyses the pathogenesis, prevalence and consequences of radiation-induced hypopituitarism (RIH) in diverse subgroups at risk. Also discussed is the impact of modern radiotherapy techniques in the prevalence of RIH, the spectrum of endocrine disorders and radiation-induced brain conditions that also occur in patients with RIH.
- 1 September 2009
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 16 (3) , 733-772
Open AccessRadiation-induced hypopituitarism
The hypothalamic–pituitary unit is a particularly radiosensitive region in the central nervous system. As a consequence, hypopituitarism commonly develops after radiation treatments for sellar and parasellar neoplasms, extrasellar brain tumours, head and neck tumours, and following whole body irradiation for systemic malignancies. Increasing tumour-related survival rates provide an expanding population at risk of developing hypopituitarism. In this population, long-term monitoring tailored to the individual risk profile is required to avoid the sequelae of untreated pituitary hormonal deficiencies and resultant decrease in the quality of life. This review analyses the pathogenesis, prevalence and consequences of radiation-induced hypopituitarism (RIH) in diverse subgroups at risk. Also discussed is the impact of modern radiotherapy techniques in the prevalence of RIH, the spectrum of endocrine disorders and radiation-induced brain conditions that also occur in patients with RIH.
- Open Access
- 1 August 2009
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 102 (8) , 311-314
Hypoparathyroidism and coeliac disease: a potentially dangerous combination
- 1 August 2009
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 102 (8) , 311-314
Open AccessHypoparathyroidism and coeliac disease: a potentially dangerous combination
- 11 February 2009
- Published by Wiley in Clinical Endocrinology
- Vol. 70 (3) , 435-438
GH replacement in patients with non‐functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence
Summary: Background Subjects with non‐functioning pituitary adenomas (NFAs) frequently develop GH deficiency due to tumour expansion or as a consequence of tumour therapy. The safety of GH replacement (GHR) in these individuals remains unclear.Objective To assess the effect of GHR on tumour recurrence in patients with NFAs solely treated by surgical removal.Patients and methods The study involved all patients with NFA who presented to the Department of Endocrinology in Oxford between January 1989 and July 2005 and were treated solely by surgical removal of the tumour. Patients with follow up < 1 year were excluded. Recurrence was diagnosed on the basis of radiological appearances (detectable tumour after gross total removal or regrowth of pre‐existing residue) on regular imaging surveillance.Results One hundred and thirty patients were included in the study, and were followed up for a mean period of 6·8 ± 4·2 years (median 5·7, range 1·2–17·6). Twenty‐three patients received GHR [16 male, 7 female, mean age at tumour diagnosis 53·7 ± 14·6 years (range 20–80)]. The mean duration of GHR was 4·6 ± 2·5 years (median 5·3, range 0·4–8·7). One hundred and seven subjects did not receive GH therapy [61 male, 46 female, mean age at tumour diagnosis 56·2 ± 14·0 years (range 20–87)]. Tumour regrowth occurred in 38 non‐GH treated subjects (36%) and 8 GHR subjects (35%). Regrowth was detected at a mean of 4·8 ± 2·8 years (range 1–11 years) in the non‐GH treated group, and at 6·5 ± 2·3 years in the GHR group. In the GHR group, recurrence occurred after a mean of 2·9 ± 2·2 years (range 0·4–5·9 years) following commencement of GH treatment. The Cox regression analysis showed that after adjusting for sex, age at tumour diagnosis, cavernous sinus invasion at diagnosis and type of tumour removal (partial or complete based on postoperative scan), GH treatment was not a significant independent predictor of recurrence (P = 0·09; hazard ratio = 0·51; 95% CI, 0·24–1·12).Conclusion GH replacement in patients with NFA treated by surgery alone is not associated with an increased risk of tumour recurrence.
- 11 February 2009
- Published by Wiley in Clinical Endocrinology
- Vol. 70 (3) , 435-438
GH replacement in patients with non‐functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence
Summary: Background Subjects with non‐functioning pituitary adenomas (NFAs) frequently develop GH deficiency due to tumour expansion or as a consequence of tumour therapy. The safety of GH replacement (GHR) in these individuals remains unclear.Objective To assess the effect of GHR on tumour recurrence in patients with NFAs solely treated by surgical removal.Patients and methods The study involved all patients with NFA who presented to the Department of Endocrinology in Oxford between January 1989 and July 2005 and were treated solely by surgical removal of the tumour. Patients with follow up < 1 year were excluded. Recurrence was diagnosed on the basis of radiological appearances (detectable tumour after gross total removal or regrowth of pre‐existing residue) on regular imaging surveillance.Results One hundred and thirty patients were included in the study, and were followed up for a mean period of 6·8 ± 4·2 years (median 5·7, range 1·2–17·6). Twenty‐three patients received GHR [16 male, 7 female, mean age at tumour diagnosis 53·7 ± 14·6 years (range 20–80)]. The mean duration of GHR was 4·6 ± 2·5 years (median 5·3, range 0·4–8·7). One hundred and seven subjects did not receive GH therapy [61 male, 46 female, mean age at tumour diagnosis 56·2 ± 14·0 years (range 20–87)]. Tumour regrowth occurred in 38 non‐GH treated subjects (36%) and 8 GHR subjects (35%). Regrowth was detected at a mean of 4·8 ± 2·8 years (range 1–11 years) in the non‐GH treated group, and at 6·5 ± 2·3 years in the GHR group. In the GHR group, recurrence occurred after a mean of 2·9 ± 2·2 years (range 0·4–5·9 years) following commencement of GH treatment. The Cox regression analysis showed that after adjusting for sex, age at tumour diagnosis, cavernous sinus invasion at diagnosis and type of tumour removal (partial or complete based on postoperative scan), GH treatment was not a significant independent predictor of recurrence (P = 0·09; hazard ratio = 0·51; 95% CI, 0·24–1·12).Conclusion GH replacement in patients with NFA treated by surgery alone is not associated with an increased risk of tumour recurrence.
- 1 January 2009
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 71 (1) , 139
Introduction
- 1 January 2009
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 71 (1) , 139
Introduction